Literature DB >> 24723381

Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort.

Bo Abrahamsen1, Henrik L Jørgensen, Anne Sofie Laulund, Mads Nybo, Thomas H Brix, Laszlo Hegedüs.   

Abstract

The relationship between thyrotoxicosis and osteoporotic fractures remains controversial, particularly in men. Register-based cohort study including all patients with a serum thyrotropin (TSH) measurement in the region of Funen 1996-2010. All TSH determinations were done in the same lab, which served all hospitals and General Practice (GP) practices in the region. Persons with raised TSH or a history of thyroid/pituitary disease or use of thyroid medications were excluded. The study population consisted of 222,138 (96%) persons with normal and 9217 (4%) with low TSH (<0.3 mIU/L). A single low TSH at baseline was associated with increased risk of hip fractures (adj HR 1.16, 95% CI 1.07-1.26, p < 0.001) but not major osteoporotic fractures (MOF, adj HR 1.06, 95% CI 0.99-1.12, p = 0.058) over a median follow-up of 7.5 years. When men were analyzed separately, results did not reach statistical significance. We found a significant association between duration of thyrotoxicosis and fracture. For each 6 months in which the mean TSH value was decreased (<0.3 mIU/L), hip fracture risk increased by a factor 1.07 (adj HR, 95% CI 1.04-1.10, p < 0.001) and MOF by 1.05 (adj HR, 95% CI 1.03-1.07, p < 0.001). Overt thyrotoxicosis was associated with an increased risk of hip fractures but not MOF. In euthyroid patients, the risk of fractures increased significantly with each SD unit of TSH decrease: Hip fracture (HR 1.45, 95% CI 1.22-1.71, p < 0.001) and MOF (HR 1.32, 95% CI 1.19-1.46, p < 0.001). In a population-based cohort, a single, first measurement of decreased TSH in patients without known thyroid disease was associated with an increased long-term risk of hip fracture, which remained significant in women but not in men after adjusting for confounders. Moreover, the risk of both hip fracture and MOF increased exponentially by the length of time during which TSH had remained low.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  Endocrine pathways; Epidemiology; Fracture risk assessment; Health Services Research; Osteoporosis

Mesh:

Substances:

Year:  2014        PMID: 24723381     DOI: 10.1002/jbmr.2244

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  27 in total

Review 1.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

2.  Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?

Authors:  Graham R Williams
Journal:  J Endocrinol Invest       Date:  2014-06-18       Impact factor: 4.256

Review 3.  Evaluation and management of skeletal disease in cancer care.

Authors:  Anuhya Kommalapati; Sri Harsha Tella; Mary Angelynne Esquivel; Ricardo Correa
Journal:  Crit Rev Oncol Hematol       Date:  2017-09-08       Impact factor: 6.312

4.  Subclinical thyroid dysfunction, bone mineral density, and osteoporosis in a middle-aged Korean population.

Authors:  K Lee; S Lim; H Park; H Y Woo; Y Chang; E Sung; H S Jung; K E Yun; C W Kim; S Ryu; M J Kwon
Journal:  Osteoporos Int       Date:  2019-11-13       Impact factor: 4.507

Review 5.  Actions of pituitary hormones beyond traditional targets.

Authors:  Mone Zaidi; Maria I New; Harry C Blair; Alberta Zallone; Ramkumarie Baliram; Terry F Davies; Christopher Cardozo; James Iqbal; Li Sun; Clifford J Rosen; Tony Yuen
Journal:  J Endocrinol       Date:  2018-03-19       Impact factor: 4.286

6.  Relationship between subclinical thyroid dysfunction and the risk of fracture: a meta-analysis of prospective cohort studies.

Authors:  Z Yan; H Huang; J Li; J Wang
Journal:  Osteoporos Int       Date:  2015-07-30       Impact factor: 4.507

Review 7.  Skeletal health in patients with differentiated thyroid carcinoma.

Authors:  M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2020-07-21       Impact factor: 4.256

8.  Thyroid function and autoimmunity are associated with the risk of vertebral fractures in postmenopausal women.

Authors:  Irene Lambrinoudaki; Eleni Armeni; Paraskevi Pliatsika; Demetrios Rizos; George Kaparos; Areti Augoulea; Andreas Alexandrou; Maria Flokatoula; Maria Creatsa; Constantinos Panoulis; Nikolaos Triantafyllou; Xenofon Papacharalambous
Journal:  J Bone Miner Metab       Date:  2016-03-29       Impact factor: 2.626

9.  Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts.

Authors:  E Tsourdi; H Wallaschofski; M Rauner; M Nauck; M Pietzner; R Rettig; T Ittermann; H Völzke; U Völker; L C Hofbauer; A Hannemann
Journal:  Osteoporos Int       Date:  2015-08-12       Impact factor: 4.507

Review 10.  Update on the treatment of hypothyroidism.

Authors:  Jacqueline Jonklaas
Journal:  Curr Opin Oncol       Date:  2016-01       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.